COVID-19 Notice

Please note, our business hours have not changed. As we navigate through the Coronavirus Pandemic, our office will continue to be responsive to all inquiries during our normal business hours. If you need to reach a doctor during non-business hours, please call 201-692-9434 and follow the emergency contact instructions. You can reach us by phone at 201-692-9434 or e-mail at

Glenpoint Centre East 300 Frank W. Burr Blvd. Teaneck, New Jersey, 07666



The CLEI Center for Keratoconus is proud to announce the recent FDA approval of corneal collagen crosslinking (CXL) for the treatment of keratoconus and corneal ectasia.  The trials were led by Dr. Peter Hersh who was medical monitor and lead author of the studies which obtained approval. We began crosslinking in 2008 and have successfully treated over a thousand patients over the years.  We continue to do research into corneal crosslinking and other aspects of keratoconus treatment to help continue the advancement of keratoconus care.

We thank our patients who participated in the trials.  Without them and our dedicated keratoconus staff, this important new treatment would not have been possible.

Click below to read the recently published paper of the U.S. crosslinking trials written by Dr. Hersh, medical monitor of the U.S. crosslinking clinical trials. 


United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment


Click here to read Dr. Hersh's new ebook, a compilation of our published articles on Corneal Collagen Crosslinking


Dr. Hersh talks to National Keratoconus Foundation about CXL

Read to see what Dr. Hersh, who is the medical monitor of the CXL trial under current review by the FDA has to say.




Active, but not presently enrolling particiants: 

The objective of this study is to investigate any difference between 2 riboflavin preparations during UV administration. The first preparation contains riboflavin in a dextran solution, which may tend to draw water out of the cornea and keep it thinner. The second preparation contains riboflavin in a hypotonic (low salt) solution without dextran, which may tend to keep the cornea more swollen. The primary goal of the study is to see if the use of hypotonic riboflavin (rather than riboflavin with dextran) better maintains consistent corneal thickness during UV administration. The second goal of the study is to determine if better maintenance of corneal thickness potentially could have benefits of better consistency of the procedure, decrease in corneal haze formation, and improved safety of the endothelial cells.

For further information about the trial call 201-883-0505 or email

For further qualifications, please click below:




Active, but not presently enrolling participants: 

We are pleased to announce a new clinical trial of transepithelial corneal collagen crosslinking (CXL) for keratoconus and corneal ectasia after previous refractive surgery. This study compares two variants of transepithelial crosslinking, otherwise know as “epi-on” crosslinking. All subjects will undergo pre-treatment with a topical anesthetic (to improve riboflavin absorption) and riboflavin 0.1% for 60 minutes. During UV irradiation, subjects will be randomized to receive one of two treatments - administration of riboflavin every 1 minute with UV light or administration of riboflavin every 2 minutes with UV light. The primary goal is to evaluate efficacy of the two transepithelial procedures. The second goal is to determine if there is equivalency between groups.
Transepithelial crosslinking, in which the epithelium is not removed, has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk of infection as no epithelial barrier will be broken, faster visual recover, and improved patient comfort in the early postoperative healing period since re-epithelialization is not required.

For further information about the trial, call 201-883-0505 or email

A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus

Study Closed

Peter Hersh, M.D. of The Cornea and Laser Eye Institute in Teaneck, NJ is conducting a clinical research trial to study an investigational treatment to stop or slow the progression of Keratoconus.

You may qualify to participate if you:

  • are 12 years of age or older
  • have been diagnosed with keratoconus
  • are able to come in for at least 8 office visits over a 12 month period

Please call the CLEI Center for Keratoconus at 201 883-0505 and ask to speak with BethAnn Hibbert for more information and to schedule an appointment.  The CLEI Center for Keratoconus is located convenient to all NYC airports, Morristown, and Princeton.

To read more about this clinical trial, please Click Here